ClinicalTrials.gg
CompletedNCT03267511Updated Jan 8, 2019Results posted

A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices

A Phase 2 interventional study of 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP in Oral Hygiene, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-08.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether spherical silica can achieve similar or greater extrinsic dental stain and plaque removal, in comparison to dentifrices containing higher concentrations of standard abrasive silica, and how the addition of 5% sodium tripolyphosphate (STP) enhances cleaning capability.

Read the detailed description

This proof of principal (PoP) single centre, randomised, examiner blind, four-treatment arm, parallel design study will be conducted in healthy participants with a propensity for extrinsic dental stain (based on the judgement of the examiner) on the facial surfaces of the anterior teeth. This study will be used to evaluate and compare the extrinsic dental stain and plaque removal of an experimental low abrasivity 0.5% spherical silica dentifrice and a marketed low abrasivity 6% standard silica abrasive dentifrice, and an experimental moderate abrasivity 1% spherical silica / 5% STP dentifrice and a marketed high abrasivity 16% standard abrasive silica / 5% STP dentifrice. Stain will be assessed using an established clinical measure of extrinsic dental stain - the MacPherson modification of the Lobene stain index (MLSI). Particpants will be stratified by baseline MLSI score (total MLSI (area [A] × intensity [I]) for the facial surfaces of the 4 anterior assessment teeth). Plaque will be assessed using an established clinical measure of plaque - the Turesky Modification of the Quigley Hein Index. Stain and plaque will be assessed at intervals over an 8 week treatment period. Plaque will be assessed at baseline and Week 8 only.

02

Conditions studied

  • Oral Hygiene
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of a personally signed and dated document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • Male and female participants who, at the time of screening, are between the ages of 18 and 65 years, inclusive.
  • Participants who are willing and able to comply with scheduled visits, treatment plan, and other study procedures.
  • Good general and mental health with, in the opinion of the investigator or medically qualified designee no and relevant abnormalities of medical history or oral examination which could impact study outcomes.
  • Good general and mental health with, in the opinion of the investigator or medically qualified designee an absence of any condition that would impact on participant safety or wellbeing, or affect the participant's ability to understand and follow study procedures and requirements.
  • In the opinion of the investigator or medically qualified designee, at screening, participants must have good oral health.
  • In the opinion of the investigator or medically qualified designee, at screening, participants must have at least 20 natural teeth including the 12 anterior teeth, gradable for Turesky Plaque Index (TPI) (Gradable teeth are those where restorative materials cover less than 25% of the tooth surface to be graded).
  • In the opinion of the investigator or medically qualified designee, at screening, participants must have the facial surfaces of at least 4 of the anterior teeth, gradable for the MLSI.
  • In the opinion of the investigator or medically qualified designee, at screening, participants must have the presence of extrinsic dental stain (judged to be formed due to dietary factors) on the facial surfaces of the anterior teeth, as determined from a visual MLSI stain assessment.
  • In the opinion of the investigator, at Visit 2, participants must have a sufficient level of extrinsic dental stain (in the opinion of the examiner) on the facial surfaces of the scorable anterior (maxillary and mandibular) teeth.
  • At Visit 3, a minimum overall pre-brushing plaque score (TPI) of ≥2.0.

Exclusion criteria

Exclusion Criteria:

  • Participants who are site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are GSK employees directly involved in the conduct of the study.
  • Participation in another clinical study or receipt of an investigational drug(s) within 30 days prior to study entry and/or during study participation.
  • Participants who have previously been enrolled in this study.
  • Acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Any condition which, in the opinion of the investigator, causes xerostomia.
  • Pregnant female participants.
  • Breastfeeding female participants.
  • Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • Unwilling or unable to comply with the lifestyle guidelines described in this protocol.
  • Recent history (within the last year) of alcohol or other substance abuse.
  • Participant is unwilling to abstain from tobacco or nicotine-containing product use (including E-cigarettes) during the treatment evaluation period.
  • Participants using the following mouth rinses, or taking the medications listed below: a) Regular use of mouthwashes containing ingredients that are known to impart staining. For example, chlorhexidine, essential oils or cetylpyridinium chloride (CPC). b) Use of a chlorhexidine, essential oil or CPC containing mouthwash within 14 days of Visit 2 or throughout the study. c) Current use of Listerine, or any antimicrobial mouth rinse. d) Use of minocycline, tetracycline or doxycycline within 30 days prior to screening. e) Use of minocycline, tetracycline or doxycycline between the screening and baseline visits. f) Daily doses of a medication and/or traditional/herbal ingredients which, in the opinion of the investigator, may affect study outcomes. For example, drugs or supplements containing metal ions known to impart staining to the enamel.
  • Participants who have the following dental exclusions: a) Received a dental prophylaxis within 8 weeks of screening. b) Gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of screening, scaling or root planning within 3 months of screening. c) Dental conditions / disease requiring immediate treatment. d) Used any professionally dispensed or over the counter bleaching/ whitening products (excluding daily use whitening dentifrices) within the past 3 months.
  • Participants who have the following specific dental exclusions for assessment teeth: a) Any tooth which, in the opinion of the investigator, appears to be non-vital based on changes in the intrinsic colour. b) Tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of screening. c) Tooth with exposed dentine which, in the opinion of the investigator, could impact grading of extrinsic dental stain; tooth with deep, defective or facial restorations; tooth used as an abutment for fixed or removable partial dentures; tooth with full crown or veneer, orthodontic bands or cracked enamel. d) Tooth with surface irregularities, discoloration due to trauma, tetracycline stain, restorations, or hypo or hyperplasic areas which, in the opinion of the investigator, would prevent consistent grading of extrinsic dental stain. e) High levels of calculus deposits which might interfere with plaque assessments at the discretion of the investigator. f) Presence of orthodontic bands or appliances, extensive crowns, partial dentures, or fixed retainers.
  • Any participant who, in the judgment of the investigator, should not participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Test Product 1

    Participants will be instructed to apply experimental dentifrice containing 5% potassium nitrate (KNO3) / 0.2542% sodium fluoride (NaF) dentifrice with 0.5% spherical silica.

    Drug: 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica

  • Experimental
    Test Product 2

    Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP.

    Drug: 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP

  • Active comparator
    Reference Product 1

    Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica.

    Drug: 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica

  • Active comparator
    Reference Product 2

    Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP.

    Drug: 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP

Interventions

  • Drug5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica

    Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).

  • Drug5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP

    Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).

  • Drug5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica

    Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).

  • Drug5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP

    Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Overall Macpherson Modification of the Lobene Stain Index (MLSI) at 8 Weeks.

    An assessment of the area and intensity of dental stain on the study teeth was performed using the MLSI to evaluate ranking order in extrinsic dental stain removal or reduction of test product 1, test product 2, reference product 1, reference product 2; after usage for 8 weeks, twice daily brushing. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI was calculated by multiplying scores of intensity and area, and was thus analyzed on a scale of 0 (best score) to 9 (worst score).

    Time frame: Baseline, Week 8 post treatment administration

Secondary outcomes

  1. Difference of Least Square Mean of Change From Baseline in Overall MLSI After 8 Weeks (Test Product 1 Versus vs. Reference Product 1)

    An assessment of the area and intensity of dental stain on the study teeth will be performed using the MLSI after usage test product 1 and reference product 1 for 8 weeks, twice daily brushing. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI will be calculated by multiplying scores of intensity and area, and will be thus analyzed on a scale of 0 (best score) to 9 (worst score).

    Time frame: Baseline, Week 8 post treatment administration

  2. Difference of Least Square Mean of Change From Baseline in Overall MLSI After 8 Weeks (Test Product 2 Versus vs. Reference Product 2)

    An assessment of the area and intensity of dental stain on the study teeth will be performed using the MLSI after usage test product 2 and reference product 2 for 8 weeks, twice daily brushing. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI will be calculated by multiplying scores of intensity and area, and will be thus analyzed on a scale of 0 (best score) to 9 (worst score).

    Time frame: Baseline, Week 8 post treatment administration

07

Results

Posted Jan 8, 2019

Participant flow

Participants were recruited from one center in USA

Participant flow — Overall Study
MilestoneTest Product 1Test Product 2Reference Product 1Reference Product 2
Started31313031
Completed31313030
Not completed0001
Withdrew: Lost to follow-up0001

Outcome measures

PrimaryChange From Baseline in Overall Macpherson Modification of the Lobene Stain Index (MLSI) at 8 Weeks.

An assessment of the area and intensity of dental stain on the study teeth was performed using the MLSI to evaluate ranking order in extrinsic dental stain removal or reduction of test product 1, test product 2, reference product 1, reference product 2; after usage for 8 weeks, twice daily brushing. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI was calculated by multiplying scores of intensity and area, and was thus analyzed on a scale of 0 (best score) to 9 (worst score).

Time frame:
Baseline, Week 8 post treatment administration
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Overall Macpherson Modification of the Lobene Stain Index (MLSI) at 8 Weeks.
Score on a scaleTest Product 1Test Product 2Reference Product 1Reference Product 2
Change From Baseline in Overall Macpherson Modification of the Lobene Stain Index (MLSI) at 8 Weeks.-0.32 ± 0.090-0.47 ± 0.090-0.38 ± 0.091-0.40 ± 0.090
Statistical analysis
  • Test Product 1 vs Reference Product 1 · ANCOVA · p = 0.6499 · Difference of least mean square: 0.06 · 95% CI -0.19 to 0.31From ANCOVA with treatment as fixed effect and baseline overall MLSI score as a covariate.
  • Test Product 2 vs Reference Product 2 · ANCOVA · p = 0.5680 · Difference of least square mean: -0.07 · 95% CI -0.33 to 0.18-0.33 to 0.18
SecondaryDifference of Least Square Mean of Change From Baseline in Overall MLSI After 8 Weeks (Test Product 1 Versus vs. Reference Product 1)

An assessment of the area and intensity of dental stain on the study teeth will be performed using the MLSI after usage test product 1 and reference product 1 for 8 weeks, twice daily brushing. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI will be calculated by multiplying scores of intensity and area, and will be thus analyzed on a scale of 0 (best score) to 9 (worst score).

Time frame:
Baseline, Week 8 post treatment administration
Reported as:
Least squares mean · Score on a scale
Difference of Least Square Mean of Change From Baseline in Overall MLSI After 8 Weeks (Test Product 1 Versus vs. Reference Product 1)
Score on a scaleTest Product 1 vs Reference Product 1
Difference of Least Square Mean of Change From Baseline in Overall MLSI After 8 Weeks (Test Product 1 Versus vs. Reference Product 1)0.06 ± 0.128
Statistical analysis
  • Test Product 1 vs Reference Product 1 · ANCOVA · p = 0.6499 · Difference of least square mean: 0.06 · 95% CI -0.19 to 0.31Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
SecondaryDifference of Least Square Mean of Change From Baseline in Overall MLSI After 8 Weeks (Test Product 2 Versus vs. Reference Product 2)

An assessment of the area and intensity of dental stain on the study teeth will be performed using the MLSI after usage test product 2 and reference product 2 for 8 weeks, twice daily brushing. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI will be calculated by multiplying scores of intensity and area, and will be thus analyzed on a scale of 0 (best score) to 9 (worst score).

Time frame:
Baseline, Week 8 post treatment administration
Reported as:
Least squares mean · Score on a scale
Difference of Least Square Mean of Change From Baseline in Overall MLSI After 8 Weeks (Test Product 2 Versus vs. Reference Product 2)
Score on a scaleTest Product 2 vs Reference Product 2
Difference of Least Square Mean of Change From Baseline in Overall MLSI After 8 Weeks (Test Product 2 Versus vs. Reference Product 2)-0.07 ± 0.128
Statistical analysis
  • Test Product 2 vs Reference Product 2 · ANCOVA · p = 0.5680 · Difference of least square mean: -0.07 · 95% CI -0.33 to 0.18Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product 10/31 (0%)0/31 (0%)3/31 (9.7%)
Test Product 20/31 (0%)0/31 (0%)1/31 (3.2%)
Reference Product 10/30 (0%)0/30 (0%)2/30 (6.7%)
Reference Product 20/31 (0%)0/31 (0%)0/31 (0%)
Most frequent other events
Most frequent other events
EventTest Product 1Test Product 2Reference Product 1Reference Product 2
TRAUMATIC ULCERInjury, poisoning and procedural complications2/310/310/300/31
MOUTH ULCERATIONGastrointestinal disorders0/310/311/300/31
PALATAL ULCERGastrointestinal disorders0/310/311/300/31
LIP ULCERATIONGastrointestinal disorders1/311/310/300/31
ANGULAR CHEILITISInfections and infestations1/310/310/300/31

Baseline characteristics

Safety population (N=123) comprised of all participants who were randomized and received at least one dose of study treatment during the study. This population was based on the treatment the participant actually received.

Age, Customized
Age, Customized(Years)Test Product 1Test Product 2Reference Product 1Reference Product 2Total
Mean45.5 ± 11.3246.2 ± 12.4241.3 ± 11.2542.9 ± 10.5744.0 ± 11.44
Sex: Female, Male
Sex: Female, Male(Participants)Test Product 1Test Product 2Reference Product 1Reference Product 2Total
Female2623192391
Male5811832
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test Product 1Test Product 2Reference Product 1Reference Product 2Total
Hispanic or Latino01023
Not Hispanic or Latino31303029120
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Test Product 1Test Product 2Reference Product 1Reference Product 2Total
American Indian or Alaska Native00000
Asian11013
Native Hawaiian or Other Pacific Islander00000
Black or African American633214
White24272728106
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • GSK Investigational Site
    Fort Wayne, Indiana 46825, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Dec 2017, 2 months.

Results were first posted in Jan 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2017
First posted
Aug 30, 2017
StartActual
Sep 25, 2017
Primary completionActual
Dec 2, 2017
CompletionActual
Dec 2, 2017
Results first posted
Jan 8, 2019
Last update
Jan 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03267511
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 30, 2017
Start date
Sep 25, 2017
Primary completion
Dec 2, 2017
Completion
Dec 2, 2017
Results posted
Jan 8, 2019
Last update
Jan 8, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
GSK Clinical Trials
study director · GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion